Mostrando 10 resultados de: 30
Filtros aplicados
Publisher
Pharmacogenomics(11)
Pharmacogenomics Journal(3)
Current Drug Targets(2)
Drug Metabolism and Drug Interactions(2)
European Journal of Clinical Pharmacology(2)
Área temáticas
Farmacología y terapéutica(23)
Enfermedades(14)
Bioquímica(12)
Fisiología humana(7)
Fisiología y materias afines(3)
Área de conocimiento
Farmacología(18)
Genética(13)
Psicopatología(5)
Medicamento(4)
Laboratorio médico(1)
Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
ReviewAbstract: CYP2D6 is described as the most relevant enzyme in the metabolism of many antipsychotic drugs. Its cPalabras claves:Antipsychotic drugs, CYP2D6, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Berecz R., Cáceres M.C., Dorado P., Penãs-Lledó E.M.Fuentes:scopusAntipsychotic drugs and QTc prolongation: The potential role of CYP2D6 genetic polymorphism
ReviewAbstract: Although the most common, and usually serious, side effects of first-generation (or typical) antipsyPalabras claves:Antipsychotic drugs, Cardiac side effects, CYP2D6, drug metabolism, QT interval lengthening, Torsades de pointes-type arrhythmiaAutores:Adrián LLerena, Berecz R., Dorado P., Penãs-Lledó E.M.Fuentes:scopusDetermination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: Application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship
ArticleAbstract: The drug-metabolizing cytochrome P450 (CYP) enzyme CYP2D6 is involved in the metabolism of several cPalabras claves:CYP2D6, debrisoquine, HPLC, Metabolic ratioAutores:Adrián LLerena, Berecz R., Cáceres M.C., Cobaleda J., Dorado P., González I.Fuentes:scopusCYP2D6 and the severity of suicide attempts
ArticleAbstract: Aim: Among people who die by suicide, an increased frequency of CYP2D6 active gene multiplication haPalabras claves:CYP2D6, severity of suicide attempt, ultrarapid metabolizerAutores:Adrián LLerena, Baca-Garca E., Blasco-Fontecilla H., Dorado P., Penãs-Lledó E.M., Vaquero-Lorenzo C.Fuentes:scopusCYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas
ArticleAbstract: Aim: In previous CYP2D6 genotyping studies in Mexican-Amerindians a very low frequency of poor metabPalabras claves:CYP2D6, Lacandones, Mexican-Mestizo, pharmacogeneticsAutores:Adrián LLerena, Alonso E., Dorado P., López-López M., Ochoa-Morales A., Ortega A., Penãs-Lledó E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusCYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans
ArticleAbstract: CYP2D6 genotype and debrisoquine metabolic ratio (MR) were analyzed in 133 Nicaraguan Mestizos (NMs)Palabras claves:Cubans, CYP2D6, debrisoquine hydroxylation, Latinos, Nicaraguans, PhenotypeAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Penãs-Lledó E.M., Pérez B., Ramirez R.Fuentes:scopusCYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population
ArticleAbstract: Purpose: Cytochrome P450 2D6 (CYP2D6) genotypes and the dextromethorphan/dextrorphan (DXM/DXT) metabPalabras claves:CYP2D6, dextromethorphan, ECUADOR, pharmacogeneticsAutores:Adrián LLerena, Dorado P., Enrique Terán, Francisco J.López Hernández, Machín E., Natalia HerasFuentes:scopusCYP2D6 polymorphism in patients with eating disorders
ArticleAbstract: CYP2D6 polymorphism is associated with variability in drug response, endogenous metabolism (that is,Palabras claves:CYP2D6, Eating disorders, pharmacogenetics, Ultrarapid metabolizersAutores:Adrián LLerena, Agüera Z., Dorado P., Estivill X., Fernández‐aranda F., Gratacòs M., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 polymorphism: Implications for antipsychotic drug response, schizophrenia and personality traits
ReviewAbstract: The CYP2D6 gene is highly polymorphic, causing absent (poor metabolizers), decreased, normal or incrPalabras claves:Adverse side effects, antipsychotics, CYP2D6, personality, pharmacogenetics, Pharmacogenomics, QTc, Schizophrenia, vulnerabilityAutores:Adrián LLerena, Dorado P., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 poor metabolizer status might be associated with better response to risperidone treatment
ArticleAbstract: The variability in the antipsychotic response is, to some extent, genetically determined. Several stPalabras claves:CYP2D6, EFFECTIVENESS, MDR1, pharmacogenetics, Risperidone, SchizophreniaAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Baca-García E., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Lopez-Castroman J., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopus